- Home
- THRD vs DSGN Comparison
THRD vs DSGN Comparison
Compare THRD & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- DSGN
- Stock Information
- Founded
- THRD 2019
- DSGN 2017
- Country
- THRD United States
- DSGN United States
- Employees
- THRD N/A
- DSGN N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- THRD Health Care
- DSGN Health Care
- Exchange
- THRD Nasdaq
- DSGN Nasdaq
- Market Cap
- THRD 232.4M
- DSGN 224.8M
- IPO Year
- THRD 2022
- DSGN 2021
- Fundamental
- Price
- THRD $5.25
- DSGN $4.01
- Analyst Decision
- THRD Hold
- DSGN Hold
- Analyst Count
- THRD 3
- DSGN 1
- Target Price
- THRD $5.00
- DSGN $4.00
- AVG Volume (30 Days)
- THRD 296.2K
- DSGN 94.1K
- Earning Date
- THRD 05-08-2025
- DSGN 05-07-2025
- Dividend Yield
- THRD N/A
- DSGN N/A
- EPS Growth
- THRD N/A
- DSGN N/A
- EPS
- THRD N/A
- DSGN N/A
- Revenue
- THRD N/A
- DSGN N/A
- Revenue This Year
- THRD N/A
- DSGN N/A
- Revenue Next Year
- THRD N/A
- DSGN N/A
- P/E Ratio
- THRD N/A
- DSGN N/A
- Revenue Growth
- THRD N/A
- DSGN N/A
- 52 Week Low
- THRD $3.18
- DSGN $2.60
- 52 Week High
- THRD $16.02
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- THRD 75.64
- DSGN 54.38
- Support Level
- THRD $5.16
- DSGN $3.67
- Resistance Level
- THRD $5.22
- DSGN $4.20
- Average True Range (ATR)
- THRD 0.04
- DSGN 0.32
- MACD
- THRD -0.03
- DSGN 0.05
- Stochastic Oscillator
- THRD 100.00
- DSGN 82.65
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.